Strong Price Performance and Market Context
On 4 December 2025, Venus Remedies touched an intraday peak of Rs.808.5, marking its highest price level in the past 52 weeks and setting an all-time high for the stock. This milestone comes after a series of gains, although the stock experienced a slight pullback today with a day change of -0.32%. Despite this minor retreat, the stock remains well above its key moving averages, trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a robust upward trend.
The stock opened with a gap up of 4.94%, reflecting positive sentiment at the start of the trading session. However, it also saw an intraday low of Rs.731.95, indicating some volatility within the day. The sector in which Venus Remedies operates, Pharmaceuticals & Biotechnology, saw the stock underperform relative to the sector by 4.86% today, yet the company’s price action remains notably strong in the broader market context.
Market Environment and Broader Indices
The broader market environment on the day showed resilience, with the Sensex recovering from an initial negative opening of -119.25 points to close higher by 0.21% at 85,284.08 points. The Sensex is currently trading just 1.03% below its own 52-week high of 86,159.02, supported by bullish moving averages where the 50-day moving average remains above the 200-day moving average. Mid-cap stocks led the market gains, with the BSE Mid Cap index rising by 0.25%, highlighting a positive market tone that complements Venus Remedies’ strong performance.
Exceptional One-Year Returns and Financial Metrics
Venus Remedies’ stock has delivered a remarkable 134.93% return over the past year, significantly outpacing the Sensex’s 5.35% return during the same period. This substantial outperformance is supported by the company’s financial results, which have shown strong growth. The company’s net profit for the latest six months stood at Rs.29.73 crores, reflecting a growth of 528.54%. Profit before tax excluding other income for the quarter reached Rs.24.78 crores, with a notable increase of 2073.68%.
Return on capital employed (ROCE) for the half year is recorded at 13.99%, the highest level for the company, while return on equity (ROE) stands at 10.5%. These metrics indicate efficient capital utilisation and profitability. The company maintains a low debt-to-equity ratio averaging zero, which suggests a conservative capital structure and limited financial leverage.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Valuation and Historical Performance
Venus Remedies is trading at a price-to-book value of 1.7, which is considered attractive relative to its peers and historical valuations. The company’s price-to-earnings growth (PEG) ratio stands at 0.1, reflecting the relationship between its price, earnings, and growth rate. Over the last three years, the stock has consistently outperformed the BSE500 index, demonstrating sustained market strength beyond the recent 12-month period.
The 52-week low for the stock was Rs.272.2, highlighting the significant appreciation in price over the past year. This wide price range underscores the stock’s momentum and the market’s evolving valuation of the company’s prospects within the Pharmaceuticals & Biotechnology sector.
Trading Dynamics and Recent Price Action
After three consecutive days of gains, Venus Remedies experienced a slight decline today, which is a common occurrence following a strong rally. The stock’s ability to maintain levels above all major moving averages suggests that the underlying trend remains intact despite short-term fluctuations. The intraday volatility, with a 5% difference between the day’s high and low, reflects active trading interest and price discovery at these elevated levels.
While domestic mutual funds currently hold no stake in the company, this does not detract from the stock’s performance or financial metrics. The company’s fundamentals, including strong profit growth and efficient capital management, continue to support its valuation and market standing.
Venus Remedies caught your attention? Explore our comprehensive research report with in-depth analysis of this micro-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth micro-cap analysis
- - Valuation assessment included
Summary of Key Indicators
Venus Remedies’ recent price milestone at Rs.808.5 is supported by a combination of strong financial results, favourable valuation metrics, and positive market trends. The company’s net profit growth of over 500% in the latest six months and a return on capital employed nearing 14% highlight operational efficiency and profitability. The stock’s performance over the past year, with returns exceeding 130%, places it well ahead of broader market indices.
Trading activity today showed a gap up at the open, followed by some intraday volatility, yet the stock remains firmly positioned above all major moving averages. This technical positioning reinforces the strength of the current trend and the significance of the new 52-week high.
While the stock’s recent underperformance relative to its sector on the day is noted, the overall trajectory remains positive, reflecting the company’s ability to sustain momentum in a competitive industry.
Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
